证券代码：300791 证券简称：仙乐健康 公告编码：2025-083 证券代码：123113 证券简称：仙乐转债 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 公司是否需追溯调整或重述以前年度会计数据 □是 √否 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 ■ 3、公司股东数量及持股情况 单位：股 ■ 注1：林培青先生名下持有公司股份28,035,072股，其中，21,902,400股（占公司总股本比例7.11%）为 其自有的公司股份，6,132,672股（占公司总股本比例1.99%）系其作为信托受托人持有的公司股份，其 作为信托受托人持有的公司股份登记在其名下，其仅对该等股份享有表决权，该等股份及其派生股份 （若有）的全部经济利益由信托合同项下的受益人享有。 持股5%以上股东 ...

Core Viewpoint - Xianle Health Technology Co., Ltd. held an investor relations event to discuss the strategic implementation and operational performance for the first half of 2025, engaging with 59 institutional investors [1][2]. Group 1: Operational Performance - In the first half of 2025, the company achieved a revenue of 2.042 billion, representing a year-on-year growth of 2.57% [3][4]. - The net profit attributable to shareholders was 161 million, reflecting a year-on-year increase of 4.30% [3][4]. - The China region reported a revenue of 818 million, a decline of 1.63%, while new consumer orders showed significant growth [3]. - The Americas generated 760 million in revenue, up 4.26%, and Europe saw a revenue increase of 21.96% to 359 million [3]. Group 2: Business Segments - The core strategic soft capsule segment grew by 6.5%, benefiting from internal business and BF collaboration [4]. - The gummy business also saw a revenue increase of 6.4%, driven by global demand and large export orders [4]. - Tablet sales surged by 33.4%, capitalizing on growth opportunities, while hard capsules grew by 11% [4]. Group 3: Cash Flow and Financial Management - The company reported a 39.7% year-on-year increase in net cash inflow from operating activities, indicating strong cash flow management [4].

（文章来源：证券日报） 证券日报网讯 8月25日晚间，仙乐健康发布公告称，2025年半年度公司实现营业收入2，041，618， 895.92元，同比增长2.57%；归属于上市公司股东的净利润为161，117，310.35元，同比增长4.30%。 ...

中国区结构优化 8月25日晚间，仙乐健康（300791）披露2025年半年度报告。报告期内，公司实现营业收入20.42亿元， 同比增长2.57%；净利润1.61亿元，同比增长4.30%；扣非净利润1.59亿元，同比增长3.25%。 在全球营养健康产业迈入智能制造与个性化消费并进的发展阶段，仙乐健康凭借新消费渠道的快速起 势、全球布局的多点突破、技术创新的持续输出，以及对未来能力的前瞻性构建，交出了一份兼具战略 定力与创新活力的中期答卷。 新旧动能转换下，仙乐健康全面拥抱新消费趋势，中国市场业务在整体结构上呈现出更均衡、更具韧性 的发展格局，整体订单量实现连续两个季度同比双位数增长。 新消费方面，仙乐健康在直播电商、跨境电商、私域和新零售等渠道均实现强劲突破，新消费客户营收 同比增长超过40%，营收占比已提升至接近50%。其中，借助MCN生态赋能，公司多个新品迅速打爆市 场，打造出高复购、高转化的爆款单品，千万级大客户的新增单品实现了100%份额合作；私域营收增 长超过200%。 与此同时，长青市场方面，仙乐健康坚持"大客户+顾问式服务"策略，持续拓展战略KA合作，推动新产 品试点上市与终端陈列优化，保持合作深 ...

Group 1: Overall Business Performance - In the first half of 2025, the company achieved a revenue of 2.042 billion, a year-on-year increase of 2.57% [3] - Net profit attributable to shareholders increased by 1.61% to 0.430 billion [3] - Revenue from the China region decreased by 1.63% to 0.818 billion, while overall order growth outpaced revenue growth [4] Group 2: International Expansion - The Americas region generated revenue of 0.760 billion, a year-on-year growth of 4.26% [4] - The European region achieved revenue of 0.359 billion, with a significant increase of 21.96% [4] - Other regions reported a revenue of 0.105 billion, reflecting a decline of 22.91% due to low base effects [4] Group 3: Product Performance - Soft capsule revenue grew by 6.5% in the first half of 2025, driven by product innovation and operational optimization [6] - The gummy business continued its growth trend with a revenue increase of 6.4%, supported by rising global demand and collaboration with well-known brand clients [7] - Tablet revenue surged by 33.4%, capitalizing on business growth opportunities [7] Group 4: Financial Metrics - The company's gross margin improved year-on-year, attributed to lean production and continuous cost reduction efforts [8] - Operating cash flow increased by 39.7%, significantly outpacing revenue growth, indicating strong cash flow management [8] Group 5: Strategic Initiatives - The company is focusing on advanced technology development and smart supply chain systems to enhance productivity in the nutrition and health industry [6] - Efforts are underway to optimize the BF business structure through potential investments or strategic partnerships [5]

证券日报网讯 8月25日晚间，仙乐健康发布公告称，公司第四届董事会第十三次会议审议通过了《2025 年半年度报告》及摘要等多项议案。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights the recent announcement by Xianle Health regarding its board meeting and the review of its 2025 semi-annual report [1] - For the first half of 2025, Xianle Health's revenue composition is as follows: soft capsules account for 46.38%, gummies for 25.31%, tablets for 9.26%, functional beverages for 5.42%, and hard capsules for 5.31% [1] - As of the report, Xianle Health has a market capitalization of 7.7 billion yuan [1] Group 2 - The article also mentions that the A-share market has seen trading volumes exceed 2 trillion yuan for eight consecutive days, indicating a robust trading environment [1] - It notes that major brokerage firms are actively recruiting for the autumn season, with 25 job positions available, reflecting a demand for talent in the industry [1]

仙乐健康(300791.SZ)发布2025年半年度报告，报告期内，公司实现营业收入20.42亿元，同比增长 2.57%。实现归属于上市公司股东的净利润1.61亿元，同比增长4.30%。实现归属于上市公司股东的扣除 非经常性损益的净利润1.59亿元，同比增长3.25%。基本每股收益0.5276元。 ...

格隆汇8月25日丨仙乐健康(300791.SZ)公布，为进一步优化公司的美国业务结构，提升公司的整体盈利 能力和市场竞争力，公司拟为控股子公司Best Formulations PC LLC(简称"BFPC")寻求投资、剥离、出售 或其他机会。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月25日，仙乐健康发布公告称，2025年上半年实现营业 收入20.42亿元，同比增长2.57%；归属于上市公司股东的净利润为1.61亿元，同比增长4.3%；归属于上 市公司股东的扣除非经常性损益的净利润为1.59亿元，同比增长3.25%。 ...